UCB: UBS upgrades stock

(CercleFinance.com) - UBS has upgrade its rating on UCB shares from "neutral" to "buy", having increased its target price for them from 90 euros to 116 euros, with the latter representing upside potential of 17% for the Belgian pharmaceutical company's stock.


"Potential approval is near for bimekizumab in psoriasis," the broker says, which says "We think success in ankylosing spondylitis is not priced in and ph3 data Q4 can drive the shares up".


Copyright (c) 2021 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.